Market Place
Sourcing Support
Senhwa Announces First Patient Dosed in the Phase II of Silmitasertib
20 Mar 2024 //
PR NEWSWIRE
Senhwa Bio Received US FDA IND Approval for Phase II Study of Silmitasertib
21 Nov 2023 //
PR NEWSWIRE
Senhwa Announces First Patient Dosed in Taiwan Phase II Study of Silmitasertib
09 Nov 2023 //
PR NEWSWIRE
Senhwa Announces IND Submission to US FDA for Phase II Study of Silmitasertib
19 Oct 2023 //
PR NEWSWIRE
Taiwan FDA approves Senhwa Biosciences’ ph II IND application of Silmitasertib
02 May 2023 //
PHARMABIZ
Senhwa Presents Positive Initial Data from Trial of Silmitasertib at AAD
28 Mar 2022 //
PRNEWSWIRE
Senhwa`s Silmitasertib Receives US FDA ODD for Biliary Tract Cancer
20 Jan 2022 //
PRNEWSWIRE
Senhwa`s Silmitasertib Receives FDA ODD in Medulloblastoma
17 Dec 2021 //
PRNEWSWIRE
Senhwa Clinical Data Abstract for Silmitasertib in BCC Accepted for 2022 AAD
16 Dec 2021 //
PRNEWSWIRE
Senhwa reports positive data from Phase II trial of Covid-19 therapy
21 Oct 2021 //
CLINICALTRIALSARENA
Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study
27 Sep 2021 //
PRNEWSWIRE
Senhwa`s Silmitasertib Receives Positive Review from Data Monitoring Committee
31 Aug 2021 //
PRNEWSWIRE
Senhwa`s Silmitasertib Receives US FDA Fast Track Designation
18 Aug 2021 //
PRNEWSWIRE
Kimshealth Thiruvananthapuram hospital invests Rs 300 crore to set up new hosP
23 Jan 2021 //
PHARMABIZ
Senhwa Announces the First Patient Enrolled in an Investigator Initiated
21 Jan 2021 //
PRNEWSWIRE
CARE GA Receives Study May Proceed Letter from US FDA to Initiate PhII Clinical
06 Nov 2020 //
BIOSPACE
Senhwa Announces Multiple IND app submissions to U.S. FDA for Silmitasertib
02 Nov 2020 //
PRNEWSWIRE
Senhwa Announces Multiple IND app submissions to U.S. FDA for Silmitasertib
02 Nov 2020 //
PRNASIA
Taiwan reports first COVID-19 patient recovery with eIND Silmitasertib treatment
15 Sep 2020 //
BIOSPECTRUM ASIA
Senhwa Reports First eIND Silmitasertib Treated Severe COVID-19 Patient
13 Sep 2020 //
PRNASIA
Senhwa Biosciences`s Silmitasertib Receives Rare Pediatric Disease Designation
07 Jul 2020 //
PRNASIA
Senhwa Bio explores Silmitasertib for COVID-19 treatment
06 Jul 2020 //
BIOSPECTRUMASIA
Coronavirus Breakthrough: New Study Highlights Senhwa Biosciences Silmitasertib
01 Jul 2020 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.